Cell-engineering firm MaxCyte's Q3 revenue beats; annual outlook lifted
MXCT•MaxCyte's preliminary third-quarter revenue rose 26% year over year to $8.1 million, beating the $7.05 million analyst consensus. The company raised its 2026 revenue outlook to about $34 million from $30 million to $32 million.
1. Revenue and outlook
MaxCyte reported preliminary third-quarter revenue of $8.1 million, above the $7.05 million consensus estimate from five analysts and up 26% year over year. The company raised its 2026 revenue guidance to about $34 million from $30 million to $32 million.
2. Drivers and breakdown
MaxCyte said the quarter was driven by accelerated instrument purchasing from a large customer and milestone revenue from an SPL partner, the second milestone achieved in 2026. The company expects 2026 core business revenue of about $28 million, up from prior guidance of $25 million to $27 million, and SPL Program-related revenue of about $6 million, up from $5 million.
